Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;31(8):616-622.
doi: 10.1007/s12149-017-1190-3. Epub 2017 Jul 7.

Early stimulated thyroglobulin for response prediction after recombinant human thyrotropin-aided radioiodine therapy

Hee Jeong Park  1 , Jung-Joon Min  1 , Hee-Seung Bom  1 , Jahae Kim  2 , Ho-Chun Song  2 , Seong Young Kwon  3
Affiliations

Early stimulated thyroglobulin for response prediction after recombinant human thyrotropin-aided radioiodine therapy

Hee Jeong Park et al. Ann Nucl Med. 2017 Oct.

Abstract

Objective: Measurement of recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin (Tg) is generally recommended 72 h after the second rhTSH injection. However, due to the acute effect of I-131 on thyrocytes, Tg measured after radioiodine therapy (RIT) would not accurately reflect the thyroid tissue burden. We aimed to determine predictive values of serum Tg level measured just before rhTSH-aided RIT and to compare the results obtained just after RIT in patients with differentiated thyroid carcinoma (DTC).

Methods: We evaluated 150 patients with DTC who underwent rhTSH-aided RIT (2.96-6.66 GBq) after total thyroidectomy between 2009 and 2014. Serum Tg level was measured 24 h (early Tg) and 72 (or 96) h (delayed Tg) after the second rhTSH injection. An excellent response was defined based on the latest American Thyroid Association Guidelines. Univariate and multivariate analyses were performed for early Tg, delayed Tg, and other clinical variables.

Results: In the multivariate analysis, tumor size [odds ratio (OR) 1.716; 95% confidence interval (CI) 1.019-2.882; p = 0.042] and early Tg level (OR 2.012; 95% CI 1.384-2.925, p < 0.001) independently predicted excellent responses. The cutoff for the best early Tg level to predict a non-excellent response was 2.0 ng/mL. Delayed Tg was not a significant predictor (OR 0.992; 95% CI 0.969-1.015; p = 0.492).

Conclusions: Early stimulated Tg significantly predicted therapeutic response after rhTSH-aided RIT in patients with DTC. Therefore, serum Tg should be measured before RIT to predict therapeutic responses.

Keywords: Differentiated thyroid carcinoma; Radioiodine therapy; Recombinant human thyrotropin; Therapeutic response; Thyroglobulin.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Results of the receiver-operating characteristic (ROC) curve analysis for the early thyroglobulin levels that predict non-excellent responses after rhTSH-aided radioiodine therapy
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Pacini F. Follow-up of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2002;29:S492–S496. doi: 10.1007/s00259-002-0847-9. - DOI - PubMed
    1. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297–306. doi: 10.1056/NEJM199801293380506. - DOI - PubMed
    1. Taïeb D, Sebag F, Cherenko M, Baumstarck-Barrau K, Fortanier C, Farman-Ara B, et al. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study. Clin Endocrinol (Oxf) 2009;71:115–123. doi: 10.1111/j.1365-2265.2008.03424.x. - DOI - PubMed
    1. Lee J, Yun MJ, Nam KH, Chung WY, Soh E-Y, Park CS. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid. 2010;20:173–179. doi: 10.1089/thy.2009.0187. - DOI - PubMed
    1. Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366:1663–1667. doi: 10.1056/NEJMoa1108586. - DOI - PubMed

MeSH terms